SecBot SecBot
8-K ·Filed Nov 5, 2026

INM

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed11d 19h ago SEC0001062993-26-005760
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The merger with Mentari Therapeutics remains subject to closing conditions; monitor for a subsequent 8-K announcing the merger's completion or any delays. The CVR terms and potential payouts are not yet specified.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$13.21
T+0 close · Nov 5, 2026 · via day close
Latest settled
+17.79%
T+1 · $15.56 · next T+5 due 5d ago
Vs SPY
+17.48%
α at T+1
Latest observation
+47.04%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $13.21entry
  2. T+1 · 11d ago +17.79%α +17.48% · $15.56
  3. T+5 · due 5d ago Pending
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals (INM) reported shareholder approval of all proposals at its annual meeting, including a 1-for-10 reverse stock split, a name change to Mentari Therapeutics, and a merger with Mentari Therapeutics. The reverse split reduced outstanding shares from 5,493,735 to approximately 549,374, and the company will issue contingent value rights (CVRs) to shareholders of record in connection with the pending merger.

Key Facts

  • Shareholders approved all 10 proposals at the November 4, 2026 meeting, including the Nasdaq Share Issuance Proposal (97.3% for), the Return of Capital Proposal (97.3% for), the Redomestication Proposal (88.8% for), and the Stock Plan Proposal (88.6% for).
  • A 1-for-10 reverse stock split was completed, reducing outstanding shares from 5,493,735 to approximately 549,374.
  • The company changed its name to Mentari Therapeutics, Inc., effective November 4, 2026.
  • A merger with Mentari Therapeutics (via two merger subs) is pending, with closing conditions yet to be satisfied.
  • Shareholders of record as of November 5, 2026 will receive one CVR per post-consolidation share, entitling them to contingent payments under a CVR Agreement.
  • Directors elected: Andrew Hull, Nicole Lemerond, Neil Klompas, John Bathery, and Eric A. Adams.

Financial Impact

Reverse stock split reduced share count by 90% from 5,493,735 to ~549,374; no financial figures for the merger or CVR payments were disclosed.

share countdilution

Risk Factors

  • The merger may not close on the anticipated timeline or at all if closing conditions are not satisfied.
  • Post-merger combined company may require substantial additional funding.
  • Nasdaq must approve the initial listing application of the combined company.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001062993-26-005760
Document: form8k.htm0001062993-26-005760
Document: 0001062993-26-005760-index-headers.html0001062993-26-005760
Document: 0001062993-26-005760-index.html0001062993-26-005760
Document: 0001062993-26-005760.txt0001062993-26-005760

Track record

22 reports on INM

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $13.21 Now $19.87 +50.42% settles Dec 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
  5. Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
  6. Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
  7. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
  8. Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
  9. Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
  10. Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026